167 related articles for article (PubMed ID: 37551674)
21. [China expert recommendations on anaplastic lymphoma kinase-tyrosine kinase inhibitors treatment for advanced non-small cell lung cancer (2024 edition)].
;
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):473-485. PubMed ID: 38317359
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
24. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
[TBL] [Abstract][Full Text] [Related]
25. Canadian perspectives: update on inhibition of
Melosky B; Cheema P; Agulnik J; Albadine R; Bebb DG; Blais N; Burkes R; Butts C; Card PB; Chan AMY; Hirsh V; Ionescu DN; Juergens R; Morzycki W; Poonja Z; Sangha R; Tehfe M; Tsao MS; Vincent M; Xu Z; Liu G
Curr Oncol; 2018 Oct; 25(5):317-328. PubMed ID: 30464681
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event reporting system database.
Zhang J; Qiu T; Zhou Y; Wu S; Chen E
Expert Opin Drug Saf; 2023; 22(9):849-856. PubMed ID: 37026465
[TBL] [Abstract][Full Text] [Related]
27. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors.
Zhou F; Yang Y; Zhang L; Cheng Y; Han B; Lu Y; Wang C; Wang Z; Yang N; Fan Y; Wang L; Ma Z; Zhang L; Yao Y; Zhao J; Dong X; Zhu B; Zhou C
ESMO Open; 2023 Jun; 8(3):101560. PubMed ID: 37230029
[TBL] [Abstract][Full Text] [Related]
28. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
Schmid S; Cheng S; Chotai S; Garcia M; Zhan L; Hueniken K; Balaratnam K; Khan K; Patel D; Grant B; Raptis R; Brown MC; Xu W; Moriarty P; Shepherd FA; Sacher AG; Leighl NB; Bradbury PA; Liu G
Clin Lung Cancer; 2023 Jan; 24(1):40-50. PubMed ID: 36270866
[TBL] [Abstract][Full Text] [Related]
29. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
30. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
[TBL] [Abstract][Full Text] [Related]
31. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
[TBL] [Abstract][Full Text] [Related]
32. Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials.
Yoneda KY; Scranton JR; Cadogan MA; Tassell V; Nadanaciva S; Wilner KD; Stollenwerk NS
Clin Lung Cancer; 2017 Sep; 18(5):472-479. PubMed ID: 28373069
[TBL] [Abstract][Full Text] [Related]
33. Update of Diagnosis and Targeted Therapy for ALK
Wang QA; Chen HW; Wu RC; Wu CE
Curr Treat Options Oncol; 2023 Dec; 24(12):1683-1702. PubMed ID: 37938503
[TBL] [Abstract][Full Text] [Related]
34. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
[No Abstract] [Full Text] [Related]
35. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
Koshikawa K; Terada J; Abe M; Iwasawa S; Sakayori M; Yoshioka K; Hirasawa Y; Kasai H; Kawasaki Y; Tsushima K; Tatsumi K
Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
38. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
[TBL] [Abstract][Full Text] [Related]
39. Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.
Gemma A; Kusumoto M; Kurihara Y; Masuda N; Banno S; Endo Y; Houzawa H; Ueno N; Ohki E; Yoshimura A
J Thorac Oncol; 2019 Apr; 14(4):672-682. PubMed ID: 30521972
[TBL] [Abstract][Full Text] [Related]
40. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
